Actively Recruiting
Phase 1 Study of Single-Dose CD19CD20 Dual-Target CAR-T Lentiviral Therapy for Adults with Relapsed or Refractory B-cell Malignancies
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-05-14
30
Participants Needed
6
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of a new CD19CD20 Dual-Target in vivo CAR-T Lentiviral product in adults aged 18 years or older with relapsed or refractory B-cell malignancies. This Phase I clinical trial focuses on patients with certain blood cancers who have not responded to previous treatments or whose disease has returned. The study aims to understand how well this novel cell therapy works and its safety profile. Participants will receive a single infusion of the CD19CD20 Dual-Target in vivo CAR-T Lentiviral product. Before the infusion, some patients may receive bridging therapy if needed to control their disease. The study includes several phases screening to determine eligibility, possible bridging therapy, treatment with the CAR-T product, and a follow-up period lasting up to about two years to monitor responses and side effects. During the study, participants will be closely monitored through clinical evaluations and laboratory tests to assess tumor response and the therapys effects on the body. Key measures include tracking adverse events, drug levels in blood and bone marrow, and immune response. Researchers will also evaluate overall survival, progression-free survival, time to response, and duration of response. The total study participation spans approximately two years after treatment, with safety and efficacy assessments throughout this period.
CONDITIONS
Brief Title
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Research Team
F
FAN Lei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here